4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Idiopathic Pulmonary Fibrosis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 402 ongoing clinical trials involving Idiopathic Pulmonary Fibrosis
Of the 402 trials,156 trials are in Phase II
Furthermore, 141 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Idiopathic Pulmonary Fibrosis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Idiopathic Pulmonary Fibrosis, a respiratory condition. Asia-pacific boasts the highest number of ongoing clinical trials involving Idiopathic Pulmonary Fibrosis. Europe and North America are among some of the other prominent regions involved in Idiopathic Pulmonary Fibrosis-related drug trials.

Boehringer Ingelheim International GmbH: The leading ongoing Idiopathic Pulmonary Fibrosis related clinical trials sponsor

Boehringer Ingelheim International GmbH, the Germany-based pharmaceutical company, is the top sponsor for Idiopathic Pulmonary Fibrosis-related ongoing clinical trials.

Pliant Therapeutics Inc, University of Alabama at Birmingham, F. Hoffmann-La Roche Ltd, Celon Pharma SA, and FibroGen Incare a few other notable sponsors involving Idiopathic Pulmonary Fibrosis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Idiopathic Pulmonary Fibrosis

Nintedanib (Ofev, Cyendiv, Sevcad), Pirfenidone (Esbriet, Pirespa), and Prednisone (Rayos, Lodotra, Nocasio) are among the key marketeddrugs involving Idiopathic Pulmonary Fibrosis.

Nintedanib (Ofev, Cyendiv, Sevcad) is an indolinone-derivative, acts as an antineoplastic agent. Nintedanib functions via the following Mechanism of Action:Fibroblast Growth Factor Receptor 1 Inhibitor; Fibroblast Growth Factor Receptor 2Inhibitor; Fibroblast Growth Factor Receptor 3 Inhibitor; Platelet Derived Growth Factor Receptor Alpha Inhibitor; Platelet Derived Growth Factor Receptor BetaInhibitor; Proto Oncogene Tyrosine Protein Kinase SrcInhibitor; Receptor Type Tyrosine Protein Kinase FLT3Inhibitor; Tyrosine Protein Kinase Lck Inhibitor; Tyrosine Protein Kinase Lyn Inhibitor; Vascular Endothelial Growth Factor Receptor 1 Inhibitor; Vascular Endothelial Growth Factor Receptor 2 Inhibitor; Vascular Endothelial Growth Factor Receptor 3 Inhibitor.

Nintedanib is indicated for the treatment of Idiopathic Pulmonary Fibrosis, and several other indications including Systemic Sclerosis (Scleroderma), Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Interstitial Lung Fibrosis. Nintedanib was first approved in 2014 and is formulated as soft gelatin capsules for oral route of administration. The drug is marketed globally including the US, the UK, and Japan by Boehringer Ingelheim group (Boehringer Ingelheim International GmbH, Boehringer Ingelheim Ltd UK, etc).

Pirfenidone (Esbriet, Pirespa)is an 9t, and antifibrotic agent. Pirfenidone acts by reducing the production of fibroblasts and pro-fibrogenic substances in the lungs of Idiopathic Pulmonary Fibrosis (IPF), thus slowing disease progression. The exact mechanism of action is unknown. Esbriet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF). The drug is marketed globally including the United States, Australia, France, Germany, and Japan byF. Hoffmann-La Roche Ltd.Pirfenidone was first approved in 2008and is formulated as hard gelatin capsules, tablets and film-coated tablets for oral route of administration.